Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Supports FluMist Use, Releases Lots For 2016 Flu Season

Executive Summary

Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.


Related Content

AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval
FluMist May Not Get CDC Seal Of Approval For Several Years
AstraZeneca Hopes To Save FluMist In US With Foreign Data
Keeping Track: FDA Celebrates Thanksgiving With Approval Cornucopia
CSL Behring – 'The Biggest Company Nobody Has Ever Heard Of' – Raises Its Voice
Flu Vaccines: Quadrivalent Advances In 2015-16 Season; GSK Drops Trivalent


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts